A big heart trial missed, and the Lp(a) test still matters
Evidence: StrongMen 21-35Ad-safe topic
A major trial found that lowering Lp(a) on its own did not cut heart events, and its researchers say knowing your number is still a smart one-time step.
Hosted video lesson
Coming soon
Our Academy host will teach this lesson on camera. Read it below today.
What the research found
1In a trial of 8,350 adults with past heart disease and high Lp(a), an experimental monthly injection cut Lp(a) by about 78%, yet major heart events were almost identical after a median 4.7 years: 12.3% versus 12.1% on placebo.
2Results stayed neutral even in people with the highest starting levels, 90 mg/dL or higher, and in each part of the combined outcome, including heart attack, stroke and heart-related death.
3Lp(a) is largely set by your genes, and the trial's researchers still urge everyone to have it measured, because knowing it helps estimate heart risk and guide action on changeable risks such as LDL cholesterol and blood pressure.
The fine print. This was one trial of one experimental drug in people who already had heart disease and very well controlled cholesterol and blood pressure, so it does not answer whether lowering Lp(a) helps people without heart disease. Participants averaged about 60 years old and were 27% women and 78% white, so for men aged 21 to 35 the takeaway is the one-time test and steady care of changeable risks, not this treatment.
Ask a licensed provider
"Has my Lp(a) ever been measured, and if it is high, which changeable numbers, such as LDL cholesterol and blood pressure, should we watch more closely?"
Source: Lp(a)HORIZON Investigators (Nissen SE, senior author). N Engl J Med. 2026, with extended analyses in NEJM Evidence; presented at American Heart Association Scientific Sessions 2026, Nov 7, 2026 (randomized trial, n=8,350). Open the paper
For your business
Post it as a calm two-slide carousel, what the new trial found and why the one-time test still counts, and invite viewers to review their heart labs with a licensed provider.
Post-ready caption
A big heart trial missed, and the Lp(a) test still matters
What should be on a modern lab panel?
In a trial of 8,350 adults with past heart disease and high Lp(a), an experimental monthly injection cut Lp(a) by about 78%, yet major heart events were almost identical after a median 4.7 years: 12.3% versus 12.1% on placebo. Results stayed neutral even in people with the highest starting levels, 90 mg/dL or higher, and in each part of the combined outcome, including heart attack, stroke and heart-related death.
The fine print: This was one trial of one experimental drug in people who already had heart disease and very well controlled cholesterol and blood pressure, so it does not answer whether lowering Lp(a) helps people without heart disease. Evidence level: Strong.
Ask a licensed provider: "Has my Lp(a) ever been measured, and if it is high, which changeable numbers, such as LDL cholesterol and blood pressure, should we watch more closely?" Start at hoolongevity.com.
Want your own branded telehealth storefront? HOO Health builds it for you: $0 to start, no sign-up fee, no MLM, no quotas. joinhoohealth.com
Source: Lp(a)HORIZON Investigators (Nissen SE, senior author). N Engl J Med. 2026, with extended analyses in NEJM Evidence; presented at American Heart Association Scientific Sessions 2026, Nov 7, 2026 (randomized trial, n=8,350).
Education only, not medical advice. Rx programs require an online visit with a licensed provider. Results vary.
#HealthEducation #Labpanels #Longevity #Wellness #Telehealth #HOOHealth